comparemela.com
Home
Live Updates
Aptose Reports Results for the Second Quarter 2023 : comparemela.com
Aptose Reports Results for the Second Quarter 2023
─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc...
Related Keywords
Toronto ,
Ontario ,
Canada ,
Seoul ,
Soult Ukpyolsi ,
South Korea ,
United States ,
Canadian ,
American ,
Aptose Biosciences ,
Susan Pietropaolo ,
Aptose Biosciences Inc ,
Hanmi Pharmaceutical Inc ,
Corporate Communications Investor Relations ,
Toronto Stock Exchange ,
Nasdaq ,
American Society Of Hematology ,
European School Of Haematology ,
Exchange Commission ,
Response Rate ,
Venetoclax Doublet ,
Evaluable Patients ,
Patients Who Failed Prior Venetoclax ,
Data Guide ,
Accelerated Approval Path ,
Hanmi Pharmaceutical Commits Investment ,
Chief Executive ,
Hanmi Pharmaceutical ,
Juhyun Lim ,
Complete Response ,
Common Shares ,
Nasdaq Capital ,
Keystone Capital ,
American Society ,
Annual Meeting ,
Investor Relations ,
United States Securities ,
Nasdaq Apto ,
Nc ,
Pml ,
Aptose ,
Hematology ,
Uspetinib ,
Pto ,
Ups ,
comparemela.com © 2020. All Rights Reserved.